2-羟基乙基环己烷羧酸酯 | 16179-44-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-羟基乙基环己烷羧酸酯
• 中文别名: 2-羟基乙基环己羧酸酯
• 英文名称: 2-hydroxyethyl cyclohexanecarboxylate
• CAS: 16179-44-5
• 化学式: C₉H₁₆O₃
• mdl: MFCD30478335
• 分子量: 172.224
• InChiKey: HNBNKZUJQWPLIO-UHFFFAOYSA-N

物化性质

• 沸点：
  262.55°C (rough estimate)
• 密度：
  1.0500

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2916209090

反应信息

• 作为产物：
  描述：

  2-环己基-1,3-二氧戊环 在 叔丁基过氧化氢 、 potassium carbonate 、 1-(过氧化叔丁基)-1,2-苯碘酰-3(H)-酮 作用下， 以 苯 为溶剂， 反应 24.0h， 以62%的产率得到2-羟基乙基环己烷羧酸酯
  参考文献：
  名称：

  环缩醛与高价叔丁基过氧-lambda（3）-碘的氧化环裂解。

  摘要：

  [反应：请参见文本]在室温下，在叔丁基过氧化氢和碳酸钾存在下，在室温下将环缩醛暴露于1-叔丁基过氧-1,2-苯并恶多酚-3（1H）-一会导致氧化环裂解通过中间体叔丁基过氧原酸酯转化为乙二醇单酯。

  DOI：

  10.1021/ol016202x

文献信息

• Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
  申请人：Gallop A. Mark

  公开号：US20060111325A1

  公开（公告）日：2006-05-25

  Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of making prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of using prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed.

  3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的酰氧烷基氨基甲酸酯前药，包括3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的酰氧烷基氨基甲酸酯前药的药物组合物，制备3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的前药的方法，使用3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的前药的方法，以及用于治疗或预防痉挛或胃食管反流病等疾病或紊乱的药物组合物。还公开了适用于口服的酰氧烷基氨基甲酸酯前药、3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的持续释放口服剂型。
• The Effect of pH Control on the Selective Ruthenium-Catalyzed Oxidation of Ethers and Alcohols with Sodium Hypochlorite
  作者：Luca Gonsalvi、Isabel W. C. E. Arends、Pasi Moilanen、Roger A. Sheldon

  DOI：10.1002/adsc.200303124

  日期：2003.12

  Highly selective oxidations of ethers to esters or lactones and of secondary alcohols to ketones were achieved using catalytic amounts of various Ru precursors and the theoretical amount of NaOCl. Reactions were carried out in biphasic solvent mixtures at constant pH 9–9.5 via either feed-on-demand addition of HCl and NaOH or in the presence of NaHCO3/Na2CO3 buffer. The catalyst could be easily recycled

  使用催化量的各种Ru前体和理论量的NaOCl，可以实现醚至酯或内酯的高选择性氧化，以及仲醇至酮的高选择性氧化。通过按需进料添加HCl和NaOH或在NaHCO 3 / Na 2 CO 3缓冲液的存在下，在恒定pH 9-9.5的双相溶剂混合物中进行反应。该催化剂可以容易地再循环至少4次，而选择性只有很小的损失。通常通过简单的相分离和有机溶剂的蒸发来回收产物。还描述了催化剂前体，添加剂和pH控制方法的影响。
• Retardation film, method for producing the same, polarizing plate and liquid crystal display
  申请人：Inagaki Shinji

  公开号：US20070134446A1

  公开（公告）日：2007-06-14

  A method of producing a long roll retardation film comprising the sequential steps of: (a) casting a film forming material on an endless support to form a long roll film; (b) stretching the long roll film in a lateral direction of the long roll film while both edges of the long roll film are held employing a plurality of clips for each of the edges in a tenter (First Process); (c) reducing distances in the lateral direction between the clips holding the both edges of the long roll film while the edges of the long roll film are held continuously from First Process with the clips (Second Process); (d) enlarging the distances in the lateral direction between the clips holding the both edges of the long roll film while the edges of the long roll film are held continuously from Second Process with the clips (Third Process).

  一种制造长卷延迟膜的方法，包括以下步骤：(a)在无限支撑上铸造成膜形成材料，形成长卷膜;(b)在张力机上用多个夹子夹住长卷膜的两个边缘，沿长卷膜的横向方向拉伸长卷膜（第一步骤）;(c)在第一步骤中，保持夹子夹住长卷膜的两个边缘，同时减小夹子之间的横向距离（第二步骤）;(d)在第二步骤中，保持夹子夹住长卷膜的两个边缘，同时增大夹子之间的横向距离（第三步骤）。
• Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
  申请人：——

  公开号：US20040142857A1

  公开（公告）日：2004-07-22

  The present invention provides gemcitabine prodrugs, methods of making gemcitabine prodrugs, pharmaceutical compositions of gemcitabine prodrugs and methods of using gemcitabine prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as cancer or viral infections.

  本发明提供了吉西他滨原药、制作吉西他滨原药的方法、吉西他滨原药的药物组合物以及使用吉西他滨原药及其药物组合物治疗或预防癌症或病毒感染等疾病或紊乱的方法。
• Al2O3/MeSO3H (AMA) as a new reagent with high selective ability for monoesterification of diols
  作者：Hashem Sharghi、Mona Hosseini Sarvari

  DOI：10.1016/s0040-4020(03)00518-0

  日期：2003.5

  A new facile method for moncesterification of diols has been developed. A variety of diols, in particular oligoethylene glycols, were selectively monoesterified in excellent yields by reaction with aromatic and aliphatic acids in the presence Of Al2O3/MeSO3H as a new reagent without use of any solvents. (C) 2003 Elsevier Science Ltd. All rights reserved.